Venus Remedies receives approval for pain reliever drug Trois in Singapore
The company is holding talks with various pharmaceutical firms for tie-ups to market Trois in Singapore
BS B2B Bureau B2B Connect | Chandigarh

Pawan Chaudhary, Chairman and Managing Director, Venus Remedies, said, “This is a great opportunity for us to capture a sizeable share in this segment of the Singapore pharma market. Trois has a huge potential in Singapore, where 10% people are diagnosed with arthritis, 73.4% of the office workers suffer from musculoskeletal disorders and 20% of the population above the age of 65 suffers from symptoms of osteoarthritis.”
Chaudhary said the worldwide size of the topical pain management market is $4 billion, and, going by global projections, Trois has the potential of becoming a $250-million product once launched internationally.
Also Read
“Trois is the safest known topical product for management of pain and inflammation associated with rheumatic disorders. It is 30% more effective than conventional products, as proven through a series of toxicity and safety studies. It has 150% enhanced retention for longer effect, improved relief and better mobility,” said Dr Manu Chaudhary, Joint Managing Director and Director, Research, Venus Remedies.
A pioneer in translational medicine, Venus has filed the product, process and use patent for Trois in 46 countries. While the company has already received the patent from South Africa, New Zealand and now Singapore, it is on the verge of getting patent grants from the US, Canada, Europe.
Acknowledged as the Best Innovation for 2011 jointly by the Lockheed Martin Foundation, IC2 Texas, US, Indo-US Science and Technology Forum and the Department of Science and Technology, Government of India, Trois was launched in India last year.
More From This Section
Don't miss the most important news and views of the day. Get them on our Telegram channel
First Published: Sep 26 2014 | 2:48 PM IST

